Skip to main content
HairCited

Asynchronous Teledermatology for Non-Scarring Alopecia: A Retrospective Study.

Aliyyat Afolabi, Elijah Brown, Edra K Ha, Joseph C English
Other Telemedicine reports 2025
PubMed DOI CC-BY PDF
<\/script>\n
`; }, get iframeSnippet() { const domain = 'haircited.com'; const params = 'pmid\u003D40918047'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style



      
      
    

Widget powered by . Free, no account required.

Study Design

Tipo di studio
retrospective cohort study
Dimensione del campione
321
Intervento
Asynchronous Teledermatology for Non-Scarring Alopecia: A Retrospective Study. Minoxidil (OTC) and clobetasol for mild cases; prescription medications for moderate-severe. Specifi
Comparatore
Placebo
Direzione dell'effetto
Positive
Rischio di bias
High

Abstract

BACKGROUND: Non-scarring alopecia, including androgenetic alopecia (AGA), alopecia areata (AA), telogen effluvium (TE), and traction alopecia (TA), significantly impacts psychosocial well-being. Access to specialized dermatologic care for these conditions is often limited, particularly in underserved populations. Asynchronous teledermatology has emerged as a potential solution to extend care to these groups. OBJECTIVE: To evaluate the diagnostic utility and treatment patterns of asynchronous teledermatology for non-scarring alopecia and examine its role in improving care access across diverse populations within the University of Pittsburgh Medical Center (UPMC) network. METHODS: A retrospective study of 321 asynchronous teledermatology cases of non-scarring alopecia from 2022 to 2023 was conducted using the UPMC medical record system. Diagnosist, treatment type, and demographic data were analyzed. Longitudinal outcomes and adherence data were not consistently available. RESULTS: AA was the most common diagnosis (59.5%), followed by AGA (26.5%), TE (7.5%), and TA (5.0%). A definitive diagnosis was made remotely in 91.3% of cases; only 8.7% required in-person follow-up. Treatment included over-the-counter therapies such as minoxidil and clobetasol, with prescription medications used for moderate to severe cases. Racial demographics reflected high engagement from Black (22.7%) and Asian (12.9%) patients, with 41.7% of patients residing outside Pittsburgh. CONCLUSION: Asynchronous teledermatology is an effective tool for diagnosing and managing non-scarring alopecia, facilitating timely intervention and improving access to dermatologic care. Future studies should access patient satisfaction, long-term outcomes, and implementation strategies to further expand equitable teledermatology access.

Full Text

PDF
Loading PDF...

Tables

Table 1.

 Patients in 2022 (n = 154)Patients in 2023 (n = 167)
Primary hair loss pattern  
 Alopecia/areata11477
 Traction alopecia511
 AGA2263
 TE1212
 Other15
Appointment Setting  
 e-Derm146157
 e-Consult: Outpatient710
 Inpatient10

Table 2.

CharacteristicsPatients in 2022 (n = 154) (%)Patients in 2023 (n = 167) (%)
Demographics  
 Age, mean (SD)39.2 ± (14.2)37.3 ± (13.2)
Gender  
 Male40.2645.51
 Female59.7454.49
Race/ethnicity  
 NH White53.2560.48
 NH Black22.7222.75
 NH Asian15.5810.18
 Hispanic1.230.599
 Other/unreported4.545.39

Table 3.

Alopecia subtypeOTC treatments (%)Prescription treatments (%)Education materials (%)Other recommendations (%)
Alopecia/Areata86 (45.0%)58 (30.4%)173 (90.6%)51 (26.7%)
Androgenetic Alopecia (AGA)69 (81.2%)31 (36.5%)81 (95.3%)7 (8.2%)
Telogen Effluvium (TE)13 (54.2%)2 (8.3%)24 (100%)7 (29.2%)
Traction Alopecia (TA)9 (56.3%)3 (18.8%)15 (93.8%)3 (18.8%)
Other0 (0%)4 (80%)3 (60%)1 (20%)

References

  1. Psychological profile and quality of life of patients with alopecia areata Skin Appendage Disord, 2019
  2. Alopecia areata Nat Rev Dis Primers, 2017
  3. Teledermatology as a tool to improve access to care for medically underserved populations: A retrospective descriptive study J Am Acad Dermatol, 2016
  4. Measurement of Health-Related Quality of Life in Patients with Hair Loss JAMA Dermatol
  5. Teledermatology in alopecia: A systematic review JAAD Int, 2024
  6. Teledermatology: An evidence map of systematic reviews Syst Rev, 2024
  7. Alopecia areata: An update on etiopathogenesis, diagnosis, and management Clin Rev Allergy Immunol, 2021
  8. Diagnostic reliability in teledermatology: A systematic review and a meta-analysis BMJ Open, 2023
  9. Barriers and facilitators to skin cancer prevention among Hispanics: A qualitative study BMC Public Health, 2024
  10. British association of dermatologists’ guidelines for the management of alopecia areata 2012 Br J Dermatol, 2012

Used In Evidence Reviews

Similar Papers